CONTEXT: Lipase maturation factor 1 (LMF1) gene is a novel candidate gene in severe hypertriglyceridemia. Lmf1 is involved in the maturation of lipoprotein lipase (LPL) and hepatic lipase in endoplasmic reticulum. To date only one patient with severe hypertriglyceridemia and related disorders was found to be homozygous for a nonsense mutation in LMF1 gene (Y439X). OBJECTIVE: The objective of the study was to investigate LMF1 gene in hypertriglyceridemic patients in whom mutations in LPL, APOC2, and APOA5 genes had been excluded. RESULTS: The resequencing of LMF1 gene led to the discovery of a novel homozygous nonsense mutation in one patient with severe hypertriglyceridemia and recurrent episodes of pancreatitis. The mutation causes a G>A substitution in exon 9 (c.1395G>A), leading to a premature stop codon (W464X). LPL activity and mass were reduced by 76 and 50%, respectively, compared with normolipidemic controls. The proband over the years has shown a good response to treatment. The proband's son, heterozygous for the W464X, shows normal plasma triglyceride levels. CONCLUSIONS: We identified the second novel pathogenic mutation in LMF1 gene in a patient with severe hypertriglyceridemia. LPL deficiency in our patient was milder than in the carrier of the Y439X previously described.
CONTEXT: Lipase maturation factor 1 (LMF1) gene is a novel candidate gene in severe hypertriglyceridemia. Lmf1 is involved in the maturation of lipoprotein lipase (LPL) and hepatic lipase in endoplasmic reticulum. To date only one patient with severe hypertriglyceridemia and related disorders was found to be homozygous for a nonsense mutation in LMF1 gene (Y439X). OBJECTIVE: The objective of the study was to investigate LMF1 gene in hypertriglyceridemicpatients in whom mutations in LPL, APOC2, and APOA5 genes had been excluded. RESULTS: The resequencing of LMF1 gene led to the discovery of a novel homozygous nonsense mutation in one patient with severe hypertriglyceridemia and recurrent episodes of pancreatitis. The mutation causes a G>A substitution in exon 9 (c.1395G>A), leading to a premature stop codon (W464X). LPL activity and mass were reduced by 76 and 50%, respectively, compared with normolipidemic controls. The proband over the years has shown a good response to treatment. The proband's son, heterozygous for the W464X, shows normal plasma triglyceride levels. CONCLUSIONS: We identified the second novel pathogenic mutation in LMF1 gene in a patient with severe hypertriglyceridemia. LPL deficiency in our patient was milder than in the carrier of the Y439X previously described.
Authors: Valentina Sukonina; Aivar Lookene; Thomas Olivecrona; Gunilla Olivecrona Journal: Proc Natl Acad Sci U S A Date: 2006-11-06 Impact factor: 11.205
Authors: Osnat Ben-Zeev; Maryam Hosseini; Ching-Mei Lai; Nicole Ehrhardt; Howard Wong; Angelo B Cefalù; Davide Noto; Maurizio R Averna; Mark H Doolittle; Miklós Péterfy Journal: J Lipid Res Date: 2011-03-28 Impact factor: 5.922
Authors: Benjamin S Roberts; Melissa A Babilonia-Rosa; Lindsey J Broadwell; Ming Jing Wu; Saskia B Neher Journal: EMBO J Date: 2018-08-01 Impact factor: 11.598
Authors: Geesje M Dallinga-Thie; Remco Franssen; Hans L Mooij; Maartje E Visser; H Carlijne Hassing; Frank Peelman; John J P Kastelein; Miklós Péterfy; Max Nieuwdorp Journal: Atherosclerosis Date: 2009-12-29 Impact factor: 5.162
Authors: Hui Z Mao; Nicole Ehrhardt; Candy Bedoya; Javier A Gomez; Diane DeZwaan-McCabe; Imran N Mungrue; Randal J Kaufman; D Thomas Rutkowski; Miklós Péterfy Journal: J Biol Chem Date: 2014-07-17 Impact factor: 5.157